ID | 61808 |
FullText URL | |
Author |
Ninomiya, Kiichiro
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kaken ID
Teraoka, Shunsuke
Internal Medicine III, Wakayama Medical University
Zenke, Yoshitaka
Department of Thoracic Oncology, National Cancer Center Hospital East
Kenmotsu, Hirotsugu
Division of Thoracic Oncology, Shizuoka Cancer Center
Nakamura, Yukiko
Department of Respiratory Medicine, Yokohama Municipal Citizen’s Hospital
Okuma, Yusuke
Department of Thoracic Oncology, National Cancer Center Hospital
Tamiya, Akihiro
Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center
Nosaki, Kaname
Department of Thoracic Oncology, National Cancer Center Hospital East
Morise, Masahiro
Department of Respiratory Medicine, Nagoya University Graduate School of Medicine
Aokage, Keiju
Department of Thoracic Surgery, National Cancer Center Hospital East
Oya, Yuko
Department of Thoracic Oncology, Aichi Cancer Center Hospital
Kozuki, Toshiyuki
Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center
Sakamoto, Tomohiro
Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Tottori University
Tanaka, Kentaro
Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University
Tanaka, Hisashi
Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine
Tanizaki, Junko
Department of Medical Oncology, Kishiwada City Hospital
Miura, Satoru
Department of Internal Medicine, Niigata Cancer Center Hospital
Mizutani, Hideaki
Department of Thoracic Oncology, Saitama Cancer Center
Miyauchi, Eisaku
Department of Respiratory Medicine, Tohoku University Hospital
Yamaguchi, Ou
Department of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center
Ebi, Noriyuki
Department of Respiratory Oncology, Iizuka Hospital
Goto, Yasushi
Department of Thoracic Oncology, National Cancer Center Hospital
Sasaki, Takaaki
Respiratory Center, Asahikawa Medical University
Daga, Haruko
Department of Medical Oncology, Osaka City General Hospital
Morita, Satoshi
Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine Kyoto University
Yamanaka, Takeharu
Department of Biostatistics, Yokohama City University School of Medicine
Amano, Shinsuke
Japan Federation of Cancer Patient Groups
Hasegawa, Kazuo
Japan Lung Cancer Alliance
Imamura, Chiyo K.
Advanced Cancer Translational Research Institute, Showa University
Suzuki, Kenichi
Division of Applied Pharmaceutical Education and Research, Hoshi University
Nakajima, Kazuko
Department of Nursing and The Division of Stem Cell Transplantation, Shizuoka Cancer Center
Nishimoto, Hitomi
Department of Nursing, Okayama University Hospital
Oizumi, Satoshi
Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center
Hida, Toyoaki
Department of Thoracic Oncology, Aichi Cancer Center Hospital
Hotta, Katsuyuki
Center for Clinical Oncology, Okayama University Hospital
Kaken ID
publons
researchmap
Takiguchi, Yuichi
Department of Medical Oncology, Chiba University Hospital
|
Abstract | Patients with NSCLC in East Asia, including Japan, frequently contain EGFR mutations. In 2018, we published the latest full clinical practice guidelines on the basis of those provided by the Japanese Lung Cancer Society Guidelines Committee. The purpose of this study was to update those recommendations, especially for the treatment of metastatic or recurrent EGFR-mutated NSCLC. We conducted a literature search of systematic reviews of randomized controlled and nonrandomized trials published between 2018 and 2019 that multiple physicians had reviewed independently. On the basis of those studies and the advice from the Japanese Society of Lung Cancer Expert Panel, we developed updated guidelines according to the Grading of Recommendations, Assessment, Development, and Evaluation system. We also evaluated the benefits of overall and progression-free survival, end points, toxicities, and patients’ reported outcomes. For patients with NSCLC harboring EGFR-activating mutations, the use of EGFR tyrosine kinase inhibitors (EGFR TKIs), especially osimertinib, had the best recommendation as to first-line treatment. We also recommended the combination of EGFR TKI with other agents (platinum-based chemotherapy or antiangiogenic agents); however, it can lead to toxicity. In the presence of EGFR uncommon mutations, except for an exon 20 insertion, we also recommended the EGFR TKI treatment. However, we could not provide recommendations for the treatment of EGFR mutations with immune checkpoint inhibitors, including monotherapy, and its combination with cytotoxic chemotherapy, because of the limited evidence present in the literature. The 2020 Japanese Lung Cancer Society Guidelines can help community-based physicians to determine the most appropriate treatments and adequately provide medical care to their patients.
|
Keywords | Non–small cell lung cancer
Epidermal growth factor receptor
Systematic review
Guidelines
|
Published Date | 2021-01-31
|
Publication Title |
JTO Clinical and Research Reports
|
Volume | volume2
|
Issue | issue1
|
Publisher | Elsevier
|
Start Page | 100107
|
ISSN | 26663643
|
Content Type |
Journal Article
|
language |
English
|
OAI-PMH Set |
岡山大学
|
Copyright Holders | © 2020 The Authors.
|
File Version | publisher
|
NAID | |
DOI | |
Related Url | isVersionOf https://doi.org/10.1016/j.jtocrr.2020.100107
|
License | http://creativecommons.org/licenses/by-nc-nd/4.0/
|
Citation | Kiichiro Ninomiya, Shunsuke Teraoka, Yoshitaka Zenke, Hirotsugu Kenmotsu, Yukiko Nakamura, Yusuke Okuma, Akihiro Tamiya, Kaname Nosaki, Masahiro Morise, Keiju Aokage, Yuko Oya, Toshiyuki Kozuki, Tomohiro Sakamoto, Kentaro Tanaka, Hisashi Tanaka, Junko Tanizaki, Satoru Miura, Hideaki Mizutani, Eisaku Miyauchi, Ou Yamaguchi, Noriyuki Ebi, Yasushi Goto, Takaaki Sasaki, Haruko Daga, Satoshi Morita, Takeharu Yamanaka, Shinsuke Amano, Kazuo Hasegawa, Chiyo K. Imamura, Kenichi Suzuki, Kazuko Nakajima, Hitomi Nishimoto, Satoshi Oizumi, Toyoaki Hida, Katsuyuki Hotta, Yuichi Takiguchi, Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations, JTO Clinical and Research Reports, Volume 2, Issue 1, 2021, 100107, ISSN 2666-3643, https://doi.org/10.1016/j.jtocrr.2020.100107.
|
Open Access (Publisher) |
OA
|
Open Archive (publisher) |
Non-OpenArchive
|